This is a collection of China’s recent pharmaceutical laws, regulations, policies, and standards, mainly issued by the following authorities:

• National Medical Products Administration (NMPA);
• NMPA’s Center for Drug Evaluation (CDE);
• National Health Commission (NHC);
• National Healthcare Security Administration (NHSA);
• National Joint Drug Procurement Office;
• Chinese Pharmacopoeia (ChP) Commission.

Contents

1. China NMPA Grants One Rx-to-OTC Switch
2. China NMPA Publishes the 57th List of RLDs
3. China NHC Adds Azvudine to COVID-19 Diagnosis and Treatment Protocol
4. China NMPA to Adopt ICH E8 (R1) and E14 Guidelines
5. CDE Seeks Public Comments on Pharmaceutical Guideline Drafts

China NMPA Grants One Rx-to-OTC Switch

On Aug. 26, NMPA granted OTC status to Omeprazole Enteric-coated Tablets, a widely used drug for gastrointestinal diseases. According to Menet Database, Omeprazole’s sales value in China’s retail market reached 1.068 billion yuan (circa 155 million USD) in 2020.

China NMPA has approved 5,041 OTC drugs, including 1,111 chemical drugs, 3,921 traditional Chinese medicines, and 9 biological products. Among the approved OTC drugs, 805 were former prescriptions drugs and granted OTC status via Rx-to-OTC switch, while 192 of the 805 have both Rx and OTC statuses.

Related: How to Sell OTC Drugs to China via Cross-Border E-Commerce

China NMPA Publishes the 57th List of RLDs

On Aug. 26, China NMPA released the 57th List of Reference Listed Drugs (RLDs). The list covers 86 RLDs, including Alcon Laboratories’ Balanced Salt Solution and Novartis Europharm Limited’s Dabrafenib Mesylate Capsules. RLDs are used to see if generic drugs are equivalent with them in quality and efficacy.

China NHC Adds Azvudine to COVID-19 Diagnosis and Treatment Protocol

On Aug. 9, China National Healthcare Commission (NHC) added Azvudine Tablets, to COVID-19 Pneumonia Diagnosis and Treatment Protocol (9th Edition). The recommended dosage is 5 mg (five 1mg tablets) per day for a course no longer than 14 days. The drug, developed by  Chinese company Genuine Biotech, is priced at 270 per bottle with 35 tablets. Thus, one course of Azvudine costs no more than 540 yuan.

China NMPA to Adopt ICH E8 (R1) and E14 Guidelines

On Aug. 12, China NMPA announced that clinical trials starting on or after July 31, 2023 shall comply with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)’s E8 (R1) Guideline: General Considerations for Clinical Studies and E14 Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. ICH E8 Guideline will then no longer be in force. NMPA’s adoption of the ICH guidelines manifests a further step in the process of aligning China’s drug registration standards with international ones.

CDE Seeks Public Comments on Pharmaceutical Guideline Drafts

[Read more at ChemLinked]

Reference Links